ORGO (Organogenesis Holdings Inc. Class A Common Stock) Stock Analysis - Financials

Organogenesis Holdings Inc. Class A Common Stock (ORGO) is a publicly traded Healthcare sector company. As of May 21, 2026, ORGO trades at $2.55 with a market cap of $319.11M and a P/E ratio of 15.59. ORGO moved +5.35% today. Year to date, ORGO is -42.18%; over the trailing twelve months it is -21.78%. Its 52-week range spans $2.04 to $7.08. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces ORGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ORGO's key financials?

ORGO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ORGO recently traded at $2.55. Market cap is $319.11M. P/E ratio is 15.59. Revenue is $564.17M.

ORGO Key Metrics

Key financial metrics for ORGO
MetricValue
Price$2.55
Market Cap$319.11M
P/E Ratio15.59
EPS$0.16
Dividend Yield0.00%
52-Week High$7.08
52-Week Low$2.04
Volume0
Avg Volume0
Revenue (TTM)$564.17M
Net Income$37.03M
Gross Margin0.00%

ORGO Annual Financials

YearRevenueNet IncomeEPS
2025$564.17M$37.03M$0.16
2023$433.14M$4.95M$0.04
2022$450.89M$15.53M$0.12
2021$468.06M$94.90M$0.74

Latest ORGO News

Recent ORGO Insider Trades

  • Leibowitz Arthur S bought 5.00K (~$13.40K) on Mar 9, 2026.
  • Driscoll Michael Joseph bought 10.00K (~$26.69K) on Mar 9, 2026.
  • NUSSDORF GLENN H sold 200.00K (~$1.03M) on Dec 16, 2025.

ORGO Analyst Consensus

1 analysts cover ORGO: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.

Common questions about ORGO

What are ORGO's key financials?
ORGO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ORGO recently traded at $2.55. Market cap is $319.11M. P/E ratio is 15.59. Revenue is $564.17M.
Is ORGO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ORGO. It does not provide personalized investment advice.
ORGO

ORGO